Gemcitabine with carboplatin for advanced intrahepatic cholangiocarcinoma: A study from North India Cancer Centre

Babu, Venkata Pradeep; Talwar, Vineet; Raina, Shubhra; Goel, Varun; Dash, Prasanta K.; Bajaj, Rajat; Sharma, Manish; Medisetty, P.; Ram, Dharma; Agrawal, Chaturbhuj; Desiraju, Koundinya; Doval, D.C.

doi:10.4103/ijc.ijc_622_17

Cited by 5 publications

(5 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3 From Indian perspective, a study done by Babu et al, the median overall survival was 10.3 months when treated with cisplatin and gemcitabine. 2 As shown in ►Table 2, the median overall survival in our study was comparable to the Indian data. Moreover, in Babu et al study, only intrahepatic cholangiocarcinoma was included.…”

Section: Discussionsupporting

confidence: 87%

“…This is similar to 7 to 11 months reported in the literature. 1 2 4 5 We also tried to identify prognostic factors affecting survival. We found patients with performance status 0-1 had better survival, coinciding with the results of study reported by Wiazzane et al ( Fig.…”

Section: Discussionmentioning

confidence: 99%

“… 1 Median overall survival is less than 1 year. 2 Majority of cases present with advanced disease. Palliative chemotherapy is the only treatment prolonging the survival.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Treatment Outcomes of Advanced Cholangiocarcinoma: A Single-Center Experience from India

Nandhagopal

Kvs

2022

South Asian J Cancer

View full text Add to dashboard Cite

Background Survival data for patients with advanced cholangiocarcinoma are very sparse in India. We performed this study to find the median overall survival of patients with advanced cholangiocarcinoma and to identify prognostic factors for survival. Methods This is a retrospective study of 30 patients with inoperable and metastatic cholangiocarcinoma treated with cisplatin and gemcitabine chemotherapy. Overall survival was estimated by the Kaplan–Meier method. Univariate and multivariate analyses were performed to determine the impact of age, gender, performance status, carbohydrate antigen (CA) 19.9, liver function test on survival. Data were analyzed using SPSS version 21. Results The mean age of the population was 47.5 years (± 14.5). The most common presenting complaint was jaundice followed by abdominal pain. Extrahepatic cholangiocarcinoma comprised of 86%. Median number of cycles was 4 and the response rate was 46.6% (partial response and stable disease) The median overall survival was 9 months (95% confidence interval = 6.0–11.8 months). The median survival of patients with Eastern Cooperative Oncology Group performance score < 2 and ≥2 were 15.6 and 4.2 months (p = 0.002), respectively. The median overall survival for patients with albumin > 3.0 g/dL was 12.1 and 4.5 months for < 3.0 g/dL (p = 0.039). Patients with CA 19.9 < 200 U/mL had a better overall survival (13.2 months) than those above 200 U/mL (5.6 months) (p = 0.001). In the multivariate analysis, performance status was found to be the only independent prognostic factor Conclusion Advanced cholangiocarcinoma has a poor prognosis. Performance status, serum albumin, and CA 19.9 were found to be prognostic.

show abstract

Section: Discussionsupporting

confidence: 87%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Treatment Outcomes of Advanced Cholangiocarcinoma: A Single-Center Experience from India

Nandhagopal

Kvs

2022

South Asian J Cancer

View full text Add to dashboard Cite

show abstract

“…Standard first line therapy for CCA is gemcitabine 1,000 mg/m 2 and cisplatin 25 mg/m 2 doublet chemotherapy administered on days 1 and 8 of a 21 day cycle, for patients with good ECOG PS of 0–1, based on the ABC-02 trial ( 79 , 80 ). The dose of gemcitabine may be reduced to 800mg/m 2 if there is pre-existing liver dysfunction ( 81 – 83 ).…”

Section: Treatmentmentioning

confidence: 99%

Update on the Genetics of and Systemic Therapy Options for Combined Hepatocellular Cholangiocarcinoma

et al. 2020

View full text Add to dashboard Cite

Combined hepatocellular-cholangiocarcinoma (cHCC-ICC) is an uncommon and aggressive form of primary liver cancer. Currently, there are no international guidelines for optimal management. For localized tumors, radical resection represents the preferred treatment option, whereas for advanced tumors, systemic therapies recommended for intrahepatic cholangiocarcinoma (ICC) and hepatocellular carcinoma (HCC) are often selected. Emerging information from comparative cohort studies, genomic and transcriptomic data sets are starting to build a case for rationalized approaches to systemic treatment in the advanced setting specific to cHCC-ICC.

show abstract

“…[6][7][8][9] A recently published study from India highlighted outcomes in CCA with the gemcitabine-carboplatin regimen and showed reasonable tolerance and outcomes. 10 With this background, we conducted a retrospective study evaluating outcomes of patients with CCA treated with CT1.…”

Section: Chemotherapeutic Regimens and Toxicitiesmentioning

confidence: 99%

Presentation and Outcomes with First-Line Chemotherapy in Advanced Cholangiocarcinomas—A Relatively Rare Component of Biliary Tract Cancers in India

Bhargava

Kumar

Simha

et al. 2020

South Asian J Cancer

View full text Add to dashboard Cite

Background Biliary tract cancers (BTCs) are a rare group of cancers with limited data with respect to advanced unresectable cholangiocarcinoma (CCA). Materials and Methods The study is a retrospective study of patients with advanced unresectable/metastatic CCA, who received first-line palliative chemotherapy (CT1) from January 2014 to March 2019 at the Tata Memorial Hospital, Mumbai. Baseline clinical characteristics, chemotherapeutic regimens, and toxicities were evaluated. Results One hundred and forty patients satisfied criteria for evaluation. Median age of the entire cohort was 57 years (range: 32–80). There were 87 patients (62.1%) with intrahepatic CCA, 35 patients (25%) with perihilar CCA, and 14 patients (10%) with distal CCA. One hundred and twelve patients (80%) had metastatic disease at presentation. Commonest CT1 regimens were gemcitabine–cisplatin (GC) in 89 patients (63.5%) and gemcitabine–oxaliplatin (GO) in 34 patients (24.3%). Sixty-three patients (45%) received second-line chemotherapy. With a median follow-up of 27 months, median progression-free survival for the entire cohort was 7.56 months (95% confidence interval [CI]: 6.23–8.88), and median OS was 12.16 months (95% CI: 10.08–14.24). Common chemotherapy-related grade 3/4 side effects included vomiting in 25 patients (17.9%), diarrhea in 23 patients (16.4%), and thrombocytopenia in 22 patients (15.7%). Conclusion The current study in advanced CCAs is the largest of its nature from India. The common regimens used as first line were GC and GO. Tolerance and overall survival appear similar to previously published data.

show abstract

Gemcitabine with carboplatin for advanced intrahepatic cholangiocarcinoma: A study from North India Cancer Centre

Cited by 5 publications

References 12 publications

Treatment Outcomes of Advanced Cholangiocarcinoma: A Single-Center Experience from India

Treatment Outcomes of Advanced Cholangiocarcinoma: A Single-Center Experience from India

Update on the Genetics of and Systemic Therapy Options for Combined Hepatocellular Cholangiocarcinoma

Presentation and Outcomes with First-Line Chemotherapy in Advanced Cholangiocarcinomas—A Relatively Rare Component of Biliary Tract Cancers in India

Contact Info

Product

Resources

About